Optimind Pharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider...
Addiction
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
The Newly Institute Reports Its Annual General and Special Meeting Voting Results and Provides an Operational Update
Calgary, Alberta--(Newsfile Corp. - December 18, 2023) - The Newly Institute ("Newly" or the "Company") is pleased to report the...
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,...
Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions
VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing...
Revive Recovery and Detox Services Clarifies NO AFFILIATION With Revive Premier Treatment Center
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located...
Silver Pines Treatment Center Achieves PsychArmor Certification as a ‘Veteran Ready’ Organization
BRENTWOOD, TN / ACCESSWIRE / December 5, 2023 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and...
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)...
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential...
Intrepid Recovery Center Unveils Innovative Partial Hospitalization Program (PHP) in West Palm Beach, Florida
Intrepid Recovery Center's Founder, John Nash Pakel, Champions the Next Phase in Addiction Treatment with the Introduction of PHP -...
BayMark Releases Whitepaper: 2023 Nationwide Opioid Use Disorder Treatment Outcomes Report
BayMark's Study Demonstrates the Path to More Successful Opioid Use Disorder TreatmentLEWISVILLE, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- BayMark,...
Pasadena Villa Outpatient Clinics in McLean and Norfolk, Virginia Are PsychArmor Certified as ‘Veteran Ready’
BRENTWOOD, TN / ACCESSWIRE / November 28, 2023 / Odyssey Behavioral Healthcare, a leading provider of mental health, eating disorder,...
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,...
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite...
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products...
Cedar Recovery Welcomes Dr. Stuart Ross as Medical Director for Cookeville Office
Cedar Recovery Expands Leadership with Dr. Stuart Ross as Medical Director for Cookeville Office, Bringing Extensive Addiction Medicine Expertise and...
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,...
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and...
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target...